Roundup Lawsuits Overshadow Pharma Growth At Bayer
Xarelto And Eylea Continue To Climb
Pharmaceutical sales hit €4.35bn helped by a strong showing in China but as the number of glyphosate plaintiffs in the US jumps to 42,700, the German group's priority is sorting out Monsanto.
You may also be interested in...
Despite its Monsanto woes, Bayer is sticking with its diversified portfolio, and is branching out into patient-facing digital health services.
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
Bayer has taken steps to address the concerns of its stockholders by pulling together a legal team for its ongoing US glyphosate litigation, and bringing on board Merck’s Vioxx lawyer.